Proteomic analysis of perfusate from in situ rat placenta perfusion

Lilong Wei1,2, Lulu Jia1, Rui Xiao1, Menglin Li1, Suanca Ma1 and Youhe Gao1*
*Correspondence: gaoyouhe@pumc.edu.cn
1Department of Physiology and Pathophysiology, National Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
2General Surgery department, Fangshan Traditional Medical Hospital of Beijing, Beijing, China.

Abstract

Background: The placenta is the most important organ for the development of the embryo and fetus because of its transport functions. Over the past several decades, a small number of proteins were tested that can cross the placenta, however, there have been no high throughput and comprehensive studies of protein crossing of the placenta.

Methods: To evaluate the in situ perfused placenta model and applicate it to investigate the protein transfer functions of the placenta, the rat placenta was perfused in situ and the proteome of the perfusate was analyzed by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) in the present study.

Results: To eliminate the effects of remnants of fetal plasma in the perfusate, a two-tailed t-test of relative quantitation based on spectral counts was performed between the perfusate and fetal plasma. Twenty two proteins in the perfusate were significantly enriched (p<0.05) in comparison to the fetal plasma. Most enriched proteins were located in the cytoplasma, membrane, or matrix. There were few plasma proteins that were obviously enriched in the perfusate when we examined alpha fetal protein as the indicator of fetal plasma remnants.

Conclusions: We generated no definite evidence that plasma proteins cross the placenta. The placenta acts as a protein barrier in perfused condition. However, some of the proteins identified in the perfusate may be useful as biomarkers of the integrity of placenta barrier and the degree of placental injury.

Keywords: Placenta perfusion, proteome, placenta barrier, placenta transport function

Introduction

The placenta is an important organ for the optimal growth and development of the embryo and fetus during pregnancy because of its major functions in the absorption of nutrients, excretion of waste products, and gas transfer [1,2]. Over the past several decades, placenta transport functions have been studied in the rat [3-6], pig [7-11], sheep [12], rabbit [13], and human [14,15]. Most of these studies focused on transfer of ions, nutrients, gas, and drugs [2,16,17], whereas protein transfer across the placenta has been rarely studied. Using an isotope labelling technique and enzyme-linked immunosorbent assay, proteins such as albumin [18-20], globulins [18-20], transferrin [18], antibodies [21,22], thyroid hormones [23,24], C-reactive protein [25], granulocyte-macrophage colony-stimulating factor [26], and protease inhibitors [27,28] have been reported to cross the placenta barrier. The number of proteins that were tested is very small compared to the thousands of plasma proteins as there have been no high throughput and comprehensive studies of protein crossing of the placenta.

Artificial perfusion of the fetal umbilical circulation of the placenta has proved very useful in understanding of the mechanisms regulating solute exchange in sheep [12], guinea pigs [7-10,29], rats [6,30,31], and humans [21]. Perfusion of the placenta in situ has been used for solute transfer studies in the rat and mouse [30,32]. In the rat, in situ placental perfusion has proven particularly useful in the investigation of the mechanisms that control placental ion transport [33]. We hypothesized that this in situ placental perfusion model may be useful for proteins transfer studies in rat.

Proteomic technology can identify a large number of proteins in one analysis. This is the first study to comprehensively investigate proteins transfer from maternal circulation to fetal circulation across the placenta using an in situ placental perfusion model combined with proteomic technology.

Materials and methods

Experiment design

The artificial perfusion of the fetal umbilical circulation of the placenta was performed and the perfusate was analyzed by proteomic technology. In our study, three placenta perfusate samples and three umbilical cord plasma samples as control were analyzed by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). After protein identifications using Mascot search algorithms, the relative protein abundance was estimated based on spectral counts and a two-tailed t-test was used to analyze significant differences in identified proteins.
between two different specimens (p<0.05).

Sample preparation
This study was approved by the Institute of Basic Medical Sciences Animal Ethics Committee at the Peking Union Medical College (Animal Welfare Assurance Number: # A5518-01). All rats were housed and handled under ethical conditions, according to the international rules of animal care as specified in the International Animal Welfare Recommendations. Pregnant Sprague-Dawley rats weighing 350 g were purchased from the Vital River Company (Beijing, China). These pregnant rats were anesthetized by pentobarbitone injection of 30 mg/kg sodium thiobutabarbital on d 21 of gestation (term=23 d). Each rat was then immobilized on its back in a thermostated (37°C) bath of isotonic saline. After laparotomy and hysterotomy, the perfusate and umbilical cord plasma were dialyzed using 6% Dextran (40 000 mol wt), and essential amino acids, and it was leakage in the experiment, that experiment was discarded. To remove the Dextran, the protein was digested in gels. The perfusate from the fetal circulation. Subsequently, 20 ml of perfusate was used in a 40 min circulatory perfusion. If there was leakage in the experiment, that experiment was discarded. The cells were removed by centrifugation at 1000 g for 15 min. The resulting perfusate or serum was then centrifuged at 12000 g for 15 min at 4°C to remove any remaining cellular debris. The supernatant was collected and frozen at -80°C [34].

Protein preparation
The perfusate and umbilical cord plasma were dialyzed using a 3 kDa dialysis bag, then ethanolamine and hydrochloric acid were added to a final concentration of 20mM, which brought the solution to a final pH of 10. The samples were loaded onto a Q-HP anion exchange column (GE company) at a flow rate of 1 ml/min, then eluted with 6M guanidine hydrochloride buffer. The eluent was replaced by water with 0.1% formic acid and concentrated with a centrifugal filter device (Centricon® Plus-20, cut-off 3 000 molecular weight; Millipore, Bedford, MA, USA).

Protein digestion in gels
To remove the Dextran, the protein was digested in gels. The extracted proteins (20 μg) were dissolved by mixing the samples with loading buffer, boiled for 5 min, and loaded onto 12% SDS-PAGE gels. Then, all of the proteins in each sample were digested and extracted according to a previously described method [35].

Mass spectrometry (MS) analysis
In our study, three analyses of liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) were performed on the placenta perfusate and umbilical cord plasma samples. For these LC-MS/MS analyses, the peptides were sequentially loaded onto a trap column (Waters, Millford, MA, USA) at a flow rate of 20 μL/min with mobile phase (0.1% formic acid, 99.9% water). The trap column effluent was then transferred to a reversed-phase microcapillary column (0.1×150 mm, packed with Magic C18, 5 μm, 200 Å; Michrom Bioresources, Inc, FOB Auburn, CA, USA) in an ACQUITY UPLC system (Waters, Millford, MA, USA). Separation of the peptides was performed at a flow rate of 500 nL/min and coupled to an online analysis by tandem MS using LTQ Orbitrap Velos (Thermo Fisher Scientific, San Jose, USA). The elution gradient for the reversed-phase column was changed from 95% solvent A (0.1% formic acid, 99.9% water) to 40% solvent B (0.1% formic acid, 99.9% acetonitrile). The run time was 60 min. The MS was programmed to acquire data in a data-dependent mode [36]. All survey scans were acquired in the Orbitrap mass analyzer and the lock mass option was enabled for the 445.120025 ion [37]. The MS survey scan was obtained for the m/z range 300–2000 amu with a resolution of 60000, followed by data-dependent MS/MS scans (isolation width of 3 m/z, dynamic exclusion for 0.5 min), and the twenty most intense ions were fragmented in the ion trap by collision-induced dissociation with a normalized collision energy of 35%, activation q value 0.25, and activation time of 10 ms.

Protein identification
Tandem mass spectra were extracted from raw files using the Mascot search engine (Matrix Science, MASCOT Daemon ver. 2.2.2) with a mass range from 600–5000 Da. The processed spectral data were then searched against the IPI rat version 3.81 protein database (39 602 sequences and 21 027 041 residues) using Mascot search algorithms (ver. 2.2.0). In each case, a reversed database was used to determine the false discovery rates (FDR). The search criteria was as follows: trypsin as a protease was allowed with a maximum of two missed cleavages, carbamidomethylation at cysteine sites was set as a fixed modification, whereas acetylation at the protein N-terminus and oxidation at methionine sites were set as variable modifications. Mass tolerances of ±10 ppm for precursor ions and 0.6 Da for fragments detected using the LTQ and the Orbitrap were used in the database search. Under these conditions, the FDR was less than 3% and the significance threshold was p<0.05.

Quantification
The relative protein abundance was estimated based on spectral counts (SCs) of each given protein [38]. To reduce the bias of the peptide amount loaded in each experiment, the SCs were normalized for each protein by dividing the SC by the total SC identified in each run [39]. A two-tailed t-test was
used to analyze significant differences in identified proteins between two different specimens (p<0.05) [40].

**Annotation**

Proteins showing significant changes were noted in the Uniprot database (http://www.uniprot.org/uniprot/) and Wikipedia (http://en.wikipedia.org/wiki/).

**Results and discussion**

**Identification of proteins in placental perfusate and umbilical cord plasma**

Proteins from three placental perfusates and umbilical cord plasma samples were identified using one dimensional LC-MS/MS. In total, 367 proteins were identified in all six MS runs (Supplement Tables S1 and S2).

**Comparison of protein patterns between placental perfusate and umbilical cord plasma**

Using a two-tailed t-test, compared to umbilical cord plasma, 22 proteins were found to have significantly higher levels of expression and 10 were found to have significantly lower levels of expression in placental perfusate (p<0.05) (Table 1) (details in Supplement Tables S1 and S2).

**Some injury-related proteins in placenta without placental barrier damaged**

Tissue specific and subcellular locations of all proteins showing significant changes (p<0.05) were analyzed. Proteins such as annexin A2, tropomyosin, nidogen-1, nidogen 2, collagen 6a3 uncharacterized protein, and Transglutaminase 2 were enriched in the perfusate. These same proteins show high levels of genetic content in the placenta of the mouse [41]. Many of these significantly enriched proteins were identified as being located in the cytoplasm, basement membranes, and the cell surface or matrix in the Uniprot database or other databases, the details of which were shown in Table 1. Based on these findings, we suggest that the placenta may be partly damaged when perfused in situ. However, physiological perfusion of the placenta in situ does not disrupt placental morphology and remains useful in the investigation of the mechanisms regulating placental transport [30,32]. These proteins may be biomarkers of early injury to the placenta while the barrier functions of the placenta remain intact.

**Placenta barrier for plasma proteins**

Alpha fetal protein (AFP) is synthesised and released from fetal liver, so it may be a good indicator of the remnants of fetal plasma. In our experiment, AFP levels were decreased significantly in the placental perfusate, which indicates that fetal plasma contamination was significantly reduced. Also, serotransferrin, heparin cofactor 2, hemoglobin alpha 2 chain, and other secreted plasma proteins were significantly decreased, which suggests that most of the fetal plasma was washed away. If a protein was enriched and noted as a plasma protein, it probably can cross the placenta barrier from the mother’s side. Hemopexin, transthyretin, and platelet factor 4 were enriched. Hemopexin is synthesized in the liver and secreted into the blood, and it has been reported that the hemopexin receptor is present in the human placenta [42], which may help hemopexin cross the placenta. The reasons for the selective enrichment of transthyretin and platelet factor 4 are not clear, however these two proteins play important physiological functions.

Some proteins can cross the placenta [19,22,24] and some mechanistic and characterization studies of proteins that cross the placenta have been performed. The effects of molecular charge and molecular size on macromolecular permeability of the fetal endothelium has been studied in the guinea pig placenta [11,43]. However, in our study, few plasma proteins were found to pass the placenta, which may be a result of our quantitative methods and the low efficiency for protein passage of the placenta. In previous studies, a small percentage of proteins passed the placental barrier over a time period of longer than 3 hours [18,19]. Our quantification method was based on spectral counts, which is a semi-quantitative method, and this approach may not reflect the small changes in protein levels across the placenta.

Antibodies have been shown to cross the placenta in studies using isotopically labelled serum proteins [22] and using an in vitro perfused human placenta model [21]. It has been determined that IgG Fc receptors are expressed by cells of the placenta, and suggested that they have a possible role in the materno fetal transmission of passive immunity [44]. That there was no obvious change in antibody levels in our study may be related to the limited perfusion time. However, the placenta would have undergone more damage if we had used a longer perfusion time. With the further development of this perfusion technique, there will be less damage made to the placenta, which will allow for longer perfusion time and possibly the identification of proteins that pass the placenta.

Stable isotope labeling with amino acids (SILAC) in vivo may be the best available isotope labeling technology because of its high labeling efficiency, high-throughput, simple operation, accurate quantitation, and wide range of applications from cell line extension to understanding organization at the whole animal level [45]. It can label a large number of proteins in one study, and these labeled proteins can be used for quantitative proteomic analysis. Furthermore, the placenta remains intact during such a study. This would be an excellent method to use in future studies of placental protein transfer.

**Conclusion**

Based on the proteomic analysis of perfusate from in situ rat placenta perfusion in our present study, few plasma proteins were obviously enriched in the perfusate when we examined alpha fetal protein as the indicator of fetal plasma remnants. We generated no definite evidence that plasma proteins cross the placenta and the placenta acts as a protein barrier in
Table 1. Significant changes in protein levels between placental perfusate and umbilical cord plasma as assessed using two-tailed t-tests.

| IPI           | Description                                      | T-value | Down/Up | Tissue (gene expression in mouse) | Subcellular location                      |
|---------------|--------------------------------------------------|---------|---------|-----------------------------------|--------------------------------------------|
| IPI00325146   | Isoform Short of Annexin A2                     | 17.2    | Up      | Placenta highly expressed         | Basement membrane, Extracellular matrix, Secreted |
| IPI00214905   | Tropomyosin alpha-4 chain                        | 13.4    | Up      | Placenta highly expressed         | Cytoplasm                                  |
| IPI00231929   | Isoform M1 of Pyruvate kinase isozymes M1/M2     | 13.2    | Up      | Placenta highly expressed         | Cytoplasm                                  |
| IPI00563457   | RGD1563545 similar to nidogen 2                  | 8.7     | Up      | Basement membrane, cell surface   |                                            |
| IPI00365081   | Desmoplakin isoform 2                            | 7.9     | Up      | Basement membrane, cell surface   |                                            |
| IPI00421429   | Junction plakoglobin                              | 7.4     | Up      | Cell junction                    |                                            |
| IPI00209416   | Ephrin-B1                                        | 6.8     | Up      | Placenta lowly expressed          | Membrane                                   |
| IPI00231136   | Nidogen-1                                        | 6.7     | Up      | Placenta highly expressed         | Basal lamina(GO)                           |
| IPI00197711   | L-lactate dehydrogenase A chain                  | 5.8     | Up      | Placenta lowly expressed          | Cytoplasm                                  |
| IPI00372786   | Isoform 1 of Nidogen-2                           | 5.5     | Up      | Placenta highly expressed         | Extracellular matrix(GO)                   |
| IPI00421832   |                                                   | 4.8     | Up      |                                   |                                            |
| IPI00372705   | Gsdma Uncharacterized protein                    | 4.7     | Up      |                                   |                                            |
| IPI00195372   | Elongation factor 1-alpha 1                      | 4.3     | Up      | Placenta lowly expressed          | Cytoplasm                                  |
| IPI00565677   | Col6a3 Uncharacterized protein                   | 4.0     | Up      | Placenta highly expressed         | Extracellular matrix(GO)                   |
| IPI008959248  | LOC683720 rCG50520-like                          | 3.5     | Up      |                                   |                                            |
| IPI00195516   | Hemopexin                                        | 3.5     | Up      | Liver highly expressed            | Secreted in plasma                         |
| IPI00205135   | Transglutaminase 2                               | 3.4     | Up      | Placenta highly expressed         | Tissue transglutaminase                    |
| IPI00208644   | COP9 signalosome complex subunit 1               | 3.4     | Up      | Placenta lowly expressed          | Cytoplasm                                  |
| IPI00199973   | Leucine-rich repeat-containing protein 51        | 3.2     | Up      |                                   | Cytoplasm                                  |
| IPI00464815   | Alpha-enolase                                    | 3.2     | Up      | Placenta lowly expressed          | Cytoplasm, membrane                        |
| IPI00324380   | Transthyretin                                    | 3.2     | Up      | Epithelium and liver              | Secreted                                   |
| IPI00206634   | Platelet factor 4                                | 2.9     | Up      |                                   | Secreted                                   |
| IPI00205036   | Hemoglobin alpha 2 chain                         | -2.8    | Down    | Placenta lowly expressed          | Secreted in plasma                         |
| IPI00886485   | Rat T-kininogen                                  | -2.9    | Down    | Placenta lowly expressed          | Secreted in plasma                         |
| IPI00782621   |                                                 | -3.4    | Down    |                                   |                                            |
| IPI00363974   | Isoform 1 of Gelsolin                            | -3.4    | Down    | Placenta lowly expressed          | Cytoplasm, Secreted                        |
| IPI00564924   | Gem (nuclear organelle) associated protein 5     | -3.4    | Down    | Placenta lowly expressed          | Secreted lowly expressed                   |
| IPI00191740   | Isoform 1 of Alpha-fetoprotein                   | -3.8    | Down    | Liver highly expressed            | Secreted lowly expressed                   |
| IPI00210947   | Serpin1 Heparin cofactor 2                       | -4.3    | Down    | Liver highly expressed            | Secreted lowly expressed                   |
| IPI00396889   | Protein convertasesubtilisin/kexin type 9        | -4.3    | Down    |                                 | Cytoplasm, Secreted                        |
| IPI00231282   | Kng1:Kng2 Isoform LMW of Kinogen-1               | -5.1    | Down    | Placenta lowly expressed          | Secreted in plasma                         |
| IPI00679202   | Tf Isoform 1 of Serotransferrin                  | -8.0    | Down    | Liver highly expressed            | Secreted in plasma                         |

doi: 10.7243/2050-2273-3-1
perfused condition. However, some of the proteins identified in the perfusate may be useful as biomarkers of the integrity of placenta barrier and the degree of placental injury.

Additional files

Supplement Table S1
Supplement Table S2

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

| Authors’ contributions                  | LW | LJ | RX | ML | SM | YG |
|----------------------------------------|----|----|----|----|----|----|
| Research concept and design            | ✓  |    |    |    |    | ✓  |
| Collection and/or assembly of data     | ✓  | ✓  | ✓  | ✓  | ✓  |    |
| Data analysis and interpretation       | ✓  |    |    |    |    |    |
| Writing the article                    | ✓  |    |    |    |    |    |
| Critical revision of the article       |    |    |    |    |    | ✓  |
| Final approval of article              |    |    |    |    |    | ✓  |
| Statistical analysis                   | ✓  |    |    |    |    |    |

Acknowledgement

This work was supported by the National Basic Research Program of China (2012CB517606, 2013CB530805), 111 Project (B08007), National Natural Science Foundation of China (31200614) and Beijing Natural Science Foundation (5132028). Key Basic Research Program of the Ministry of Science and Technology of China (2013FY114100).

Publication history

EIC: Vladimir N. Uversky University of South Florida, USA.
Received: 05-Dec-2013 Revised: 16-Jan-2014
Accepted: 19-Jan-2014 Published: 28-Jan-2014

References

1. Schneider H. Placental transport function. Reprod Fertil Dev. 1991; 3:345-53. | Article | PubMed
2. Bell AW, Hay WW, Jr. and Ehrhardt RA. Placental transport of nutrients and its implications for fetal growth. J Reprod Fertil Suppl. 1999; 54:401-10. | Article | PubMed
3. Stulc J, Stulcova B and Svihovec J. Transport of calcium across the dually perfused placenta of the rat. J Physiol. 1990; 420:295-311. | Article | PubMed Abstract | PubMed Full Text
4. Malmstrom HS, Fritz ME, Timmis DP and Van Dyke TE. Transport of calcium by the placenta of the rat. J Physiol. 1990; 420:295-311. | Article | PubMed Abstract | PubMed Full Text
5. Stulc J, Stulcova B and Svihovec J. Transport of calcium across the dually perfused placenta of the rat. J Physiol. 1990; 420:295-311. | Article | PubMed Abstract | PubMed Full Text
6. Stulc J, Stulcova B and Svihovec J. Transport of calcium across the dually perfused placenta of the rat. J Physiol. 1990; 420:295-311. | Article | PubMed Abstract | PubMed Full Text
7. Schweitz JH and Yudilevich DL. Characterization of choline transport at maternal and fetal interfaces of the perfused guinea-pig placenta. J Physiol. 1985; 366:251-60. | Article | PubMed Abstract | PubMed Full Text
8. Schroder H, Schoch C, Elwers W and Leichtweiss HP. The artificially
BS and Husain SM. Artificial perfusion of the fetal circulation of the in situ mouse placenta: methodology and validation. *Placenta*. 2006; 27 Suppl A:569-75. | Article | PubMed

33. Sibley CP. Review article: mechanisms of ion transfer by the rat placenta: a model for the human placenta? *Placenta*. 1994; 15:675-91. | PubMed

34. He P, He HZ, Dai J, Wang Y, Sheng QH, Zhou LP, Zhang ZS, Sun YL, Liu F, Wang K, Zhang JS, Wang HK, Song ZM, Zhang HR, Zeng R and Zhao X. The human plasma proteome: analysis of Chinese serum using shotgun strategy. *Proteomics*. 2005; 5:3442-53. | Article | PubMed

35. Shevchenko A, Tomas H, Havlis J, Olsen JV and Mann M. In-gel digestion for mass spectrometric characterization of proteins and proteomes. *Nat Protoc.* 2006; 1:2856-60. | Article | PubMed

36. Nagaraj N, D’Souza RC, Cox J, Olsen JV and Mann M. Feasibility of large-scale phosphoproteomics with higher energy collisional dissociation fragmentation. *J Proteome Res.* 2010; 9:6786-94. | Article | PubMed

37. Olsen JV, de Godoy LM, Li G, Macek B, Mortensen P, Pesch R, Makarov A, Lange O, Horning S and Mann M. Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap. *Mol Cell Proteomics*. 2005; 4:2010-21. | Article | PubMed

38. Liu H, Sadogov RG and Yates JR, 3rd. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. *Anal Chem.* 2004; 76:4193-201. | Article | PubMed

39. Dong MQ, Venable JD, Au N, Xu T, Park SK, Cociorva D, Johnson JR, Dillin A and Yates JR, 3rd. Quantitative mass spectrometry identifies insulin signaling targets in *C. elegans*. *Science*. 2007; 317:660-3. | Article | PubMed

40. Zhang B, VerBerkmoes NC, Langston MA, Uberbacher E, Hettich RL and Samatova NF. Detecting differential and correlated protein expression in label-free shotgun proteomics. *J Proteome Res.* 2006; 5:2909-18. | Article | PubMed

41. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, Zhang J, Soden R, Hayakawa M, Kreiman G, Cooke MF, Walker JR and Hogenscho JB. A gene atlas of the mouse and human protein-encoding transcriptomes. *Proc Natl Acad Sci U S A.* 2004; 101:6062-7. | Article | PubMed Abstract | PubMed Full Text

42. Taketani S, Kohno H, Naitoh Y and Tokunaga R. Isolation of the hemopexin receptor from human placenta. *J Biol Chem.* 1987; 262:8668-71. | Article | PubMed

43. Sibley CP, Bauman KF and Firth JA. Molecular charge as a determinant of macromolecule permeability across the fetal capillary endothelium of the guinea-pig placenta. *Cell Tissue Res.* 1983; 229:365-77. | Article | PubMed

44. A Bright CDO and M Anwar. Ontogeny and distribution of Fcy receptors in the human placenta. Transport or immune surveillance? *Journal of Anatomy.* 1994; 184:297-308.

45. Kruger M, Moser M, Issar S, Thievensen I, Lubera CA, Forner F, Schmidt S, Zanivan S, Fassler R and Mann M. SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function. *Cell.* 2008; 134:353-64. | Article | PubMed

Citation:
Wei L, Jia L, Xiao R, Li M, Ma S and Gao Y. Proteomic analysis of perfusate from in situ rat placenta perfusion. *J Proteome Sci Comput Biol*. 2014; 3:1. http://dx.doi.org/10.7243/2050-2273-3-1